Table 1.

Description of the study population.

	No WFs at diagnosis		All IPMNs
	No. of patients with progression (%)	No. of patients with no progression (%)	No. of patients with progression (%)	No. of patients with no progression (%)
Branch-duct IPMN	78 (26)	204 (68)	91 (26)	223 (63)
Mixed-type IPMN	12 (4)	3 (1)	22 (6)	9 (3)
Main-duct IPMN	1 (0.34)	0	7 (2)	2 (0.6)
Age, median (IQR), years	68 (61.0–68.0)	66 (60.0–72.0)	67 (60.0–73.0)	67 (60.0–73.0)
Follow-up time, median (IQR), months	67 (37.0–104.0)	59.99 (32.3–90.03)	60 (31.5–91.17)	61.7 (31.6–92.05)
Sex
Male	43 (14)	73 (24)	60 (17)	89 (25)
Female	48 (16)	134 (45)	60 (17)	145 (41)
BMI
<18	7 (2)	11 (4)	7 (2)	12 (3)
18–25.9	45 (15)	126 (42)	59 (16)	138 (39)
26–29.9	26 (9)	53 (18)	34 (10)	62 (18)
≥30	106 (36)	11 (4)	13 (4)	17 (5)
Not available	3 (1)	7 (2)	7 (1)	5 (1)
Smoking
No (never)	61 (20)	135 (45)	76 (22)	149 (42)
Yes	30 (10)	72 (24)	44 (12)	85 (24)
Alcohol consumption
No (never)	53 (18)	118 (40)	67 (19)	134 (38)
Yes	38 (13)	89 (30)	53 (15)	100 (28)
Type 2 diabetes
No	78 (26)	187 (63)	103 (29)	210 (60)
Yes	13 (4)	20 (7)	17 (5)	24 (7)
Cyst size at diagnosis (mm)
<15	32 (11)	125 (42)	40 (11)	133 (38)
15.1–29.9	59 (20)	82 (28)	59 (17)	84 (24)
≥30			21 (6)	17 (5)

Age and progression time are expressed in years and months, respectively. Progression means patients without WFs or HRSs and patients with WFs at diagnosis who developed the first or an additional WF or HRS during the follow-up. No progression means the no-development of new WFs or HRSs during the follow-up.

BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); IQR, interquartile range; WFs, worrisome features; HRSs, high-risk stigmata; IPMN, intraductal papillary mucinous neoplasm.